The Global Gastrointestinal Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies
Global Gastrointestinal Partnering 2014 to 2021 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Trends in Gastrointestinal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Gastrointestinal partnering agreement structure
Gastrointestinal partnering contract documents
Top Gastrointestinal deals by value
Most active Gastrointestinal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.
Global Gastrointestinal Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.
Global Gastrointestinal Partnering 2014 to 2021 includes:
- Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Gastrointestinal deal contract documents
- Comprehensive access to over 450 Gastrointestinal deal records
- The leading Gastrointestinal deals by value since 2014
- Most active Gastrointestinal dealmakers since 2014
- The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.
In Global Gastrointestinal Partnering 2014 to 2021, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
- Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Gastrointestinal Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 450 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Gastrointestinal Partnering 2014 to 2021 provides the reader with the following key benefits:
- In-depth understanding of Gastrointestinal deal trends since 2014
- Access Gastrointestinal deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Gastrointestinal partner companies
- Comprehensive access to over 450 links to actual Gastrointestinal deals entered into by the world's biopharma companies
- Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Gastrointestinal opportunities
- Uncover companies actively partnering Gastrointestinal opportunities
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in Gastrointestinal dealmaking
- 2.1. Introduction
- 2.2. Gastrointestinal partnering over the years
- 2.3. Gastrointestinal partnering by deal type
- 2.4. Gastrointestinal partnering by industry sector
- 2.5. Gastrointestinal partnering by stage of development
- 2.6. Gastrointestinal partnering by technology type
- 2.7. Gastrointestinal partnering by therapeutic indication
Chapter 3 -Financial deal terms for Gastrointestinal partnering
- 3.1. Introduction
- 3.2. Disclosed financials terms for Gastrointestinal partnering
- 3.3. Gastrointestinal partnering headline values
- 3.4. Gastrointestinal deal upfront payments
- 3.5. Gastrointestinal deal milestone payments
- 3.6. Gastrointestinal royalty rates
Chapter 4 - Leading Gastrointestinal deals and dealmakers
- 4.1. Introduction
- 4.2. Most active in Gastrointestinal partnering
- 4.3. List of most active dealmakers in Gastrointestinal
- 4.4. Top Gastrointestinal deals by value
Chapter 5 - Gastrointestinal contract document directory
- 5.1. Introduction
- 5.2. Gastrointestinal partnering deals where contract document available
Chapter 6 - Gastrointestinal dealmaking by therapeutic target
- 6.1. Introduction
- 6.2. Deals by Gastrointestinal therapeutic target
- Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2014 to 2021
- Appendix 2 - Directory of Gastrointestinal deals by deal type 2014 to 2021
- Appendix 3 - Directory of Gastrointestinal deals by stage of development 2014 to 2021
- Appendix 4 - Directory of Gastrointestinal deals by technology type 2014 to 2021
- Further reading on dealmaking
- Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent report titles from CurrentPartnering
Table of figures
- Figure 1: Gastrointestinal partnering since 2014
- Figure 2: Gastrointestinal partnering by deal type since 2014
- Figure 3: Gastrointestinal partnering by industry sector since 2014
- Figure 4: Gastrointestinal partnering by stage of development since 2014
- Figure 5: Gastrointestinal partnering by technology type since 2014
- Figure 6: Gastrointestinal partnering by indication since 2014
- Figure 7: Gastrointestinal deals with a headline value
- Figure 8: Gastrointestinal deals with upfront payment values
- Figure 9: Gastrointestinal deals with milestone payment
- Figure 10: Gastrointestinal deals with royalty rates
- Figure 11: Active Gastrointestinal dealmaking activity- 2014 to 2021
- Figure 12: Top Gastrointestinal deals by value since 2014